Autologous Transplantation With and High Dose BCNU and Melphalan Followed by Consolidation With DCEP Plus Taxol/Cisplatin in Patients With Poor Prognosis Low Grade Non-Hodgkin's Lymphoma and Chronic Lymphocyte Leukemia, Who Have Received < or = 12 Months of Standard Therapy

Inclusion Criteria

DISEASE CHARACTERISTICS: Histologically confirmed low grade follicular lymphoma, mantle
cell lymphoma, or chronic lymphocytic leukemia with no greater than 12 months of prior
standard therapy Follicular lymphoma Must have poor prognosis disease defined as any of
the following: Any nodal or extranodal tumor mass with a diameter more than 7 cm
Involvement of at least 3 nodal sites, each of which has a diameter greater than 3 cm
Systemic symptoms Substantial splenic involvement no greater than 5 cm below left costal
margin Serous effusions (ascites, pleural or pericardial effusions) Orbital or epidural
involvement Ureteral compression Leukemia presentation (at least 500/microliter) Increased
LDH level Greater than 20% bone marrow involvement Mantle cell lymphoma No mantle zone
morphology Chronic lymphocytic leukemia Must have either anemia (hemoglobin less than 10
g/dL), thrombocytopenia (less than 100,000/mm3), cytogenetic abnormalities including +12
and 11q, elevated LDH levels, labeling index at least 2%, systemic symptoms, or
hepatosplenomegaly No active CNS disease A new classification scheme for adult
non-Hodgkin's lymphoma has been adopted by PDQ. The terminology of "indolent" or
"aggressive" lymphoma will replace the former terminology of "low", "intermediate", or
"high" grade lymphoma. However, this protocol uses the former terminology.

PATIENT CHARACTERISTICS: Age: 18 to 70 Performance status: SWOG 0-2 Life expectancy: Not
specified Hematopoietic: At least 4,000/g CD34+ peripheral blood stem cells available See
Disease Characteristics Hepatic: Bilirubin no greater than 1.5 mg/dL Transaminases no
greater than 4 times upper limit of normal No active chronic hepatitis or liver cirrhosis
Renal: Creatinine no greater than 2.0 mg/dL Cardiovascular: Left ventricular ejection
fraction at least 50% Pulmonary: FEV1, FVC, and DLCO at least 50% of predicted Other: HIV
negative No active infection requiring intravenous antibiotics Not pregnant or nursing
Effective contraception required of all fertile patients

PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 4 weeks
since prior chemotherapy Endocrine therapy: Prior corticosteroids allowed Radiotherapy: At
least 4 weeks since prior local radiotherapy Surgery: Not specified